PLUVICTO is the first and only approved PSMA-targeted radioligand therapy
PLUVICTO is targeted therapy
PLUVICTO is a targeted therapy that delivers radiation treatment directly to PSMA+ cells.
1. PSMA is a biomarker that is expressed on prostate cancer cells and can be seen on a PSMA PET scan. PLUVICTO can be used to target PSMA-positive cancer cells.
2. Once PLUVICTO attaches to PSMA, it is absorbed by the cell.
3. Once PLUVICTO is absorbed by the cell, it releases radiation that can damage and kill cells that are PSMA+ and other nearby cells.
IT'S NOT CHEMOTHERAPY
PLUVICTO can target PSMA+ cells wherever they are in the body.
What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...
Approved Use
What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...
